Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 2/20 | 0.37 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021117 | 0.84 | ALDH1A1 (0.43) | ALDH1A1CES2CES1POLBAOC3 | |
| SCHEMBL28042518 | 0.79 | DEPTOR (0.42) | ALDH1A1CES2CES1POLBTSHR | |
| SCHEMBL10441686 | 0.78 | AOC3 (0.40) | ALDH1A1CES2CES1POLBAOC3 | |
| SCHEMBL6781028 | 0.77 | PTPN1 (0.34) | POLBTSHRPTPN1MEN1KMT2A | |
| SCHEMBL5429550 | 0.76 | AOC3 (0.38) | ALDH1A1CES2CES1POLBAOC3 | |
| SCHEMBL27669364 | 0.76 | POLB (0.37) | ALDH1A1CES2CES1POLBAOC3 | |
| Bicarbonate SCHEMBL29118429 | 0.75 | ALDH1A1 (0.46) | ALDH1A1CES2CES1FEN1ERCC5 | |
| SCHEMBL11048011 | 0.73 | NPSR1 (0.52) | ALDH1A1POLBTSHRMEN1KMT2A | |
| SCHEMBL10780634 | 0.70 | TSHR (0.44) | ALDH1A1FEN1ERCC5TSHRMEN1 | |
| Hydrochloric Acid SCHEMBL4510368 | 0.70 | TDP1 (0.40) | ALDH1A1CES2CES1AOC3AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6753334-B2 | PREPARING A PHENYL OR QUINOLINYL HYDRAZINE BY REDUCING THE CORRESPONDING DIAZONIUM SALT WITH ASCORBIC ACID AND HEATING; COLORLESS PRODUCT; INTERMEDIATES TO DRUGS FOR REDUCING TISSUE DAMAGE FROM ISCHEMIA OR HYPOXIA | PFIZER, INC. | 2004-06-22 | — | — | US | disclosed |
| EP-1337508-A1 | PREPARATION OF SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | Pfizer Products Inc. (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20020082274-A1 | Preparation of sodium-hydrogen exchanger type-1 inhibitors | LAMBERT JOHN F (US) | 2002-06-27 | — | — | US | disclosed |
| WO-2002044133-A1 | PREPARATION OF SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082274-A1 | Preparation of sodium-hydrogen exchanger type-1 inhibitors | SLC9A1, NHERF1, SLC9A5 | ALDH1A1 531/4885CES2 1289/4885CES1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.